A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.

Subjects who met the inclusion/exclusion criteria will administer Fexuclue Tablet once a day for four weeks after registration, regardless of their meals. If esophagitis is not treated or symptoms continue after 4 weeks of administration, the subject will continue to administer Fexuclue Tablet for 4 more weeks (maximum administration period: 8 weeks).

Inclusion criteria

• Adult men and women aged 19 to 75 years of age at the time of registration.
• A patient with erosive gastroesophageal reflux disease who is scheduled to administer Fexuclue Tab. for the first time based on the medical judgement of the researcher based on the medication authorization.
• A person who voluntarily agrees to participate in this observation study and signed the informed consent form.

Exclusion criteria

• A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet

• Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof
• Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations
• Pregnant and lactating women
• Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
• A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;
• In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study